EYEVENSYS

Eyevensys is a clinical stage, private, biotechnology company developing its innovative EyeCET platform to enable the sustained intraocular production of therapeutic proteins to treat a broad range of ophthalmic disease. EyeCET stands for the eye ciliary muscle electro-transfection technology, which uses electroporation to deliver plasmids coding for therapeutic proteins in the eye. EyeCET is safe and non-viral, and it enables the ciliary muscle cells to sustainably produce therapeutic proteins locally. Eyevensys believes its EyeCET technology can improve short and long-term therapeutic outcomes, greatly enhancing patient compliance and significantly improve the tolerability of treatment. Eyevensys’ lead product EYS606 is a potential new treatment for patients with non-infectious Uveitis (NIU), the 4th cause of blindness in the world. EYS606 uses Eyevensys’ proprietary electro-transfection injection system (ETIS) to deliver a plasmid encoding for the production of an anti-TNF alpha-alpha cytokine that has been shown to play a pivotal role in mediating intraocular inflammation in NIU. EYS606 which been granted an Orphan designation by the EMA for the treatment of NIU, has received in February 2017 the regulatory clearances from the UK MHRA and the French ANSM Health Agencies to begin a Phase I/II clinical trials. Subsequently, a multicentre clinical study has just been initiated in France and the UK.